Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evidence that amyloidogenic light chains undergo antigen-driven selection

V Perfetti1, P Ubbiali, M C Vignarelli

  • 1Research Laboratories of Biotechnology and Organ Transplantation, Clinical Immunology Unit, Department of Internal Medicine, Pavia, Italy.

Blood
|May 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing equine embryo outcomes in OPU‑ICSI systems: Insights from a large‑scale program in Brazil.

Journal of equine veterinary science·2026
Same author

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.

ESMO open·2025
Same author

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

ESMO open·2025
Same author

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

ESMO open·2025
Same author

Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus.

Orphanet journal of rare diseases·2020
Same author

Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.

European journal of neurology·2020

Light chain amyloidosis involves abnormal protein deposits. This study found that amyloid-forming light chains show evidence of antigen selection, suggesting their development from B cells with enhanced antigen-binding capabilities.

Area of Science:

  • Immunology
  • Hematology
  • Molecular Biology

Background:

  • AL amyloidosis is characterized by amyloid deposits of monoclonal light chains from bone marrow plasma cells.
  • The origin and formation process of these pathogenic light chains remain largely unknown.

Purpose of the Study:

  • To investigate the ontogenesis of pathogenic light chains in AL amyloidosis.
  • To gain insights into the processes driving light chain formation and identify potential antigen selection in amyloid clones.

Main Methods:

  • Isolation of complete variable (V) regions of light (VL) and heavy (VH) chains from amyloid clones using inverse PCR.
  • Analysis of somatic mutations in V regions compared to germline genes and assessment for intraclonal diversification.
  • Statistical analysis to detect evidence of antigen selection in amyloid V regions.

Related Experiment Videos

Main Results:

  • Amyloid V regions exhibited significant mutations compared to germline genes.
  • No association was found between mutations and intraclonal diversification.
  • Statistical evidence of antigen selection was identified in 8 out of 14 amyloid clones (7 VL, 1 VH).

Conclusions:

  • A significant proportion of AL amyloidosis clones originate from B cells selected for improved antigen binding.
  • Pathogenic light chains in AL amyloidosis display molecular evidence of this antigen-driven selection process.